Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
-- 46% of Evaluable Patients Show Stabilized Disease; BiomarkersCorrelate with Clinical Effect and Demonstrate Potential forPatient Stratification -- GERMANTOWN, Md., June 19, 2007 /PRNewswire-FirstCall/ -- AvalonPharmaceuticals, Inc. , today announced continued positive interimresults from its Phase I study of AVN944, for the treatment ofhematologic malignancies in elderly and refractory...Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
GERMANTOWN, Md., June 13, 2007 /PRNewswire-FirstCall/ -- AvalonPharmaceuticals, Inc. , today announced that it is will provide anupdate on the Phase I clinical trial of AVN944 in hematologicmalignancies on Tuesday, June 19, 2007, after the close of the U.S.financial markets. The Company will also host a conference call onWednesday, June 20, 2007 at 8 a.m. Eastern Time. Interestedinvestor...